Inactive Instrument

News Novus Therapeutics, Inc. Nasdaq

Equities

Summary

Unlock all the news: Be the first to know and act before the market!

Eledon Pharmaceuticals : Submission of Matters to a Vote of Security Holders Form 8 K	Jul. 10	PU
Eledon Pharmaceuticals, Inc. announced that it has received $2.099993 million in funding	Jul. 07	CI
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism	Jul. 02	GL
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 3000E Index	Jun. 30	CI
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell Microcap Index	Jun. 30	CI
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell Microcap Value Index	Jun. 30	CI
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 3000E Value Index	Jun. 30	CI
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	Jun. 03	GL
Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	Jun. 03	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results	May. 09	GL
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress	May. 09	GL
Eledon Pharmaceuticals, Inc. announced that it has received $49.99901 million in funding	May. 08	CI
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection	May. 07	GL
Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection	May. 07	CI
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement	May. 07	GL
Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding	May. 05	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results	Mar. 28	GL
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours	Mar. 25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Novus Therapeutics, Inc. Nasdaq

Equities

Summary

Filters